Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Lisheng Pharmaceutical Performance Brief: Net profit attributable to parent company in 2025 increased by 126.72% year-on-year
Radar Finance Text | Feng Xiuyu Edited | Li Yihui
On March 9th, Lisheng Pharmaceutical (002393) released its 2025 performance forecast, reporting an operating revenue of 1.393 billion yuan, a year-on-year increase of 4.23%. Net profit attributable to shareholders of the listed company was 418 million yuan, a year-on-year increase of 126.72%. After deducting non-recurring gains and losses, net profit attributable to shareholders was 169 million yuan, up 64.16% year-on-year. Basic earnings per share were 1.62 yuan, an increase of 125.00%.
According to Tianyancha, Lisheng Pharmaceutical was established on June 17, 1981, with a registered capital of 257.943 million yuan. The legal representative is Zhang Ping, and the registered address is No. 16, Saita North Road, Xiqing Economic Development Zone, Tianjin. Its main business involves the research, production, and sales of pharmaceutical products.
Currently, the company’s chairman is Zhang Ping, the secretary of the board is Ma Feifei, with 1,604 employees. The actual controller is the Tianjin Municipal State-owned Assets Supervision and Administration Commission.
The company has stakes in 7 subsidiaries, including Tianjin Central Pharmaceutical Co., Ltd., Tianjin Biochemical Pharmaceutical Co., Ltd., Tianjin Lisheng Investment Management Co., Ltd., Hebei Kunlun Pharmaceutical Co., Ltd., and Sanyu Pharmacy (Tianjin) Co., Ltd.
In terms of performance, the operating revenues for 2022, 2023, and 2024 were 1.147 billion yuan, 1.153 billion yuan, and 1.336 billion yuan, respectively, with year-on-year growth rates of 5.00%, 0.56%, and 15.88%. Net profits attributable to the parent were 93.6066 million yuan, 362 million yuan, and 185 million yuan, with year-on-year growth rates of -23.34%, 286.54%, and -49.00%. During the same period, the company’s asset-liability ratios were 17.80%, 15.17%, and 17.03%.
Regarding risks, Tianyancha data shows the company has 103 internal Tianyan risks, 90 surrounding risks, 107 historical risks, and 139 early warning risks.